Epilepsy, which afflicts approximately 4.7 million people in the major markets according to DRG epidemiology, is a heterogeneous condition requiring individualized treatment based largely on a patient’s seizure syndrome and seizure type. The epilepsy therapy market already comprises more than 25 antiepileptic drugs (AEDs), most of them generic, that can be effective for many patients. In this challenging market environment, most developers are targeting underserved, orphan pediatric epilepsy populations, or they are developing reformulations of existing products as rescue therapies as a path to differentiation. Understanding the trajectory of the established epilepsy market and the evolving competitive landscape in niche segments is critical for marketers of both current and emerging brands to retain market share or carve out a clinical role.

Questions Answered:

  • What is the current state of treatment in epilepsy across the G7, and what needs are left unfulfilled by approved AEDs?
  • What are the market opportunities and sales potential for agents targeting treatment-refractory focal epilepsy (e.g., cenobamate, padsevonil) and for agents targeting orphan epilepsy subpopulations (e.g., Epidiolex, Fintepla)?
  • What clinical role will recently approved (e.g., Nayzilam, Valtoco) and emerging acute rescue therapies (e.g., Libervant) play in the epilepsy market?
  • How will neurologists differentiate among current and emerging third-generation AEDs, and which of these agents will enjoy the most clinical and commercial success in the face of strong generics competition from first- and second-generation AEDs?

Markets covered: United States, France, Germany, Italy, Spain, United Kingdom, Japan.

Primary research: Approximately 20 country-specific interviews with thought-leading neurologists, supported by survey data collected for this content and other DRG research.

Epidemiology: Diagnosed prevalence of epilepsy by country, segmented by generalized and partial-onset seizures; drug-treated cases.

Emerging therapies: Phase III/PR: 5 drugs; coverage of select II products.

Market forecast features: Patient-based market forecast extending through 2028, segmented by brands/generics.

Key companies: Aquestive Therapeutics, Bial, Eisai, GW Pharmaceuticals, Lundbeck, Marinus Pharmaceuticals, Neurelis, Sanofi, SK Biopharmaceuticals, Sunovion, UCB, Zogenix.

Key drugs: Levetiracetam, lamotrigine, carbamazepine, valproates, Vimpat (lacosamide), Aptiom/Zebinix (eslicarbazepine acetate), Fycompa (perampanel), Briviact (brivaracetam), Epidiolex (CBD), Fintepla (fenfluramine), YKP-3089 (cenobamate), UCB-0942 (padsevonil), Nayzilam (intranasal midazolam), Libervant (buccal diazepam), Valtoco (intranasal diazepam).

Table of contents

  • Epilepsy - Landscape & Forecast - Disease Landscape & Forecast

Author(s): Niyati Khetarpal, Ph.D; Abey John, MPH; Bethany Christmann, PhD

"Niyati Khetarpal is a business insights analyst on the Central Nervous System, Pain, and Ophthalmology team at Decision Resources Group. In this role, she conducts primary and secondary research to analyze pharmaceutical markets, with a focus on neurology indications, including epilepsy and MS. She also has specific expertise in patent/IP research. Prior to joining the company, Niyati obtained her doctorate from the International Centre for Genetic Engineering and Biotechnology for her research on Dengue virus vaccines. She received the Fulbright-Nehru doctoral scholarship in 2014 for her research on Dengue and West Nile virus envelope proteins.”

Abey John is a medical graduate with a Master’s in Public Health and has been associated with DRG since September 2015. He works with a global team of epidemiologists in performing systematic reviews of assigned diseases and prepare forecast models for clients. He also is involved in producing analyses for pharmaceutical drug developers on the descriptive epidemiology of major drug indications in mature and developing markets and have an overall experience of three years working in different healthcare sectors across the country.

Prior to joining DRG, Abey had been working with Jhpiego (an affiliate of Johns Hopkins Medical University) in implementing Family Planning Health Programs in India with collaborating with the Government of India. He also has worked with a grassroots level NGO as a health team manager which worked for the benefit of the rural population living in the foothills of the Himalayas.

Bethany Christmann, Ph.D., has been with DRG since 2015, and is a Senior Business Insights Analyst with the Central Nervous System/Ophthalmology team. In this role, she covers the neurology space, specializing in Parkinson’s disease and epilepsy; she provides expert insight and authors primary market research and forecasting content focused on these and other neurology indications. Prior to joining DRG, Bethany earned her Ph.D. in neuroscience from Brandeis University, where she studied the cellular interactions involved in memory consolidation and their link to sleep behavior.


Related Reports

Epilepsy - Special Topics - Epilepsy Special Topics New Treatments In Epilepsy US

More than two dozen antiepileptic drugs (AEDs) are available in the United States, yet approximately one-third of epilepsy patients are refractory to

View Details

Epilepsy - Access & Reimbursement - Detailed, Expanded Analysis (US)

Despite the large number of currently marketed antiepileptic drugs (AEDs), important unmet needs remain for new therapies to treat refractory epilepsy and se...

View Details

Epilepsy - Current Treatment - Detailed, Expanded Analysis - Treatment Algorithms - Claims Data Analysis (US) Total

Epilepsy is a heterogeneous condition requiring individualized treatment—especially for patients who are persistently refractory to treatment. Neurologists consider many factors when selectin...

View Details

Epilepsy | Disease Landscape and Forecast | G7 | 2019

Epilepsy, which afflicts approximately 4.7 million people in the G7 according to DRGepidemiology, is a heterogeneous condition r...

View Details